Business

From bad to worse for Puma Biotechnology

From bad to worse for Puma Biotechnology

If you want a good example of how volatile biotechnology stocks can be, look no further than Puma Biotechnology Inc. This cancer-focused biotechnology company was founded 8 years ago and went public in 2012 with shares trading around $10 per share. In 2014 that share price rocketed to +$260 following positive clinical trials for the breast cancer drug Nerlynx, which contributed towards the company’s valuation at $10 billion. Following this, mixed research results and delays in approval processes have caused the company share price to swing wildly with the stock price plummeting almost 80% this year. Shares plunged a further 48% on Friday 2nd November after the company reported disappointing sales of $52.6 million for Nerlynx, below expectations of $58.1 million. Furthermore, Puma Biotech indicated that the percentage of patients who discontinued the use of Nerlynx as a result of adverse events had increased to about 18%, which only added to the sell-off. The good news for shareholders is that this massive sell-off is probably overdone. Nerylnx’s sales are likely to increase as the drug becomes more globally used, which may indicate that this stock is currently at a bargain price.

Read more

Climate justice for a just world

Environment

Climate justice for a just world

In mainstream discussions on climate change, there is a tendency to focus on the environmental dimensions of the issue. Increasingly, however, there is greater recognition of the need to place equal emphasis on human impacts, notably in relation to under-recognised and vulnerable groups in society affected by social injustices

By Anita Punwani
Hugh Brady to remain College President until 2030

News

Hugh Brady to remain College President until 2030

Professor Hugh Brady’s term as President of Imperial has been extended by three years until August 2030, following a unanimous approval by the College Council. In an email to students and staff, Council Chair Vindi Banga said a Search Committee commissioned in February found “extensive support for this extension”

By Guillaume Felix